TSE:MBX

Microbix Biosystems Competitors

C$0.62

+0.01 (+1.64 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

C$0.60

Now: C$0.62▼

C$0.63

50-Day Range

C$0.52

MA: C$0.58▼

C$0.63

52-Week Range

C$0.22

Now: C$0.62▼

C$0.68

Volume219,757 shs

Average Volume188,958 shs

Market CapitalizationC$67.86 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Microbix Biosystems (TSE:MBX) Vs. MDNA, EMC, NEPT, IMV, FRX, and RVX

Should you be buying MBX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Microbix Biosystems, including Medicenna Therapeutics (MDNA), Emblem (EMC), Neptune Wellness Solutions (NEPT), IMV (IMV), Fennec Pharmaceuticals (FRX), and Resverlogix (RVX).

Microbix Biosystems vs. Medicenna Therapeutics Stock

Medicenna Therapeutics (TSE:MDNA) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Medicenna Therapeutics and Microbix Biosystems' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-16.18
Microbix Biosystems	C$11.64 million	5.83	C$-5,581,797.00	C($0.05)	-12.16

Medicenna Therapeutics has higher earnings, but lower revenue than Microbix Biosystems. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicenna Therapeutics and Microbix Biosystems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	N/A	N/A
Microbix Biosystems	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Medicenna Therapeutics and Microbix Biosystems, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	0	0	0	N/A
Microbix Biosystems	0	0	0	0	N/A

Summary

Microbix Biosystems beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Microbix Biosystems vs. Emblem Stock

Emblem (CVE:EMC) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Emblem and Microbix Biosystems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
Microbix Biosystems	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Emblem and Microbix Biosystems, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0	0	0	0	N/A
Microbix Biosystems	0	0	0	0	N/A

Earnings & Valuation

This table compares Emblem and Microbix Biosystems' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	$5.71 million	43.02	C$-24,806,020.00	($0.19)	-9.89
Microbix Biosystems	C$11.64 million	5.83	C$-5,581,797.00	C($0.05)	-12.16

Microbix Biosystems has higher revenue and earnings than Emblem. Microbix Biosystems is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Summary

Microbix Biosystems beats Emblem on 3 of the 5 factors compared between the two stocks.

Microbix Biosystems vs. Neptune Wellness Solutions Stock

Microbix Biosystems (TSE:MBX) and Neptune Wellness Solutions (TSE:NEPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Microbix Biosystems and Neptune Wellness Solutions' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbix Biosystems	N/A	N/A	N/A
Neptune Wellness Solutions	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Microbix Biosystems and Neptune Wellness Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbix Biosystems	0	0	0	0	N/A
Neptune Wellness Solutions	0	0	1	0	3.00

Neptune Wellness Solutions has a consensus target price of C$4.63, indicating a potential upside of 212.50%. Given Neptune Wellness Solutions' higher probable upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Microbix Biosystems.

Earnings and Valuation

This table compares Microbix Biosystems and Neptune Wellness Solutions' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbix Biosystems	C$11.64 million	5.83	C$-5,581,797.00	C($0.05)	-12.16
Neptune Wellness Solutions	C$52.78 million	4.64	C$-223,415,550.00	C($1.35)	-1.10

Microbix Biosystems has higher earnings, but lower revenue than Neptune Wellness Solutions. Microbix Biosystems is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Neptune Wellness Solutions beats Microbix Biosystems on 4 of the 7 factors compared between the two stocks.

Microbix Biosystems vs. IMV Stock

IMV (TSE:IMV) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares IMV and Microbix Biosystems' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMV	C$3,000.00	78,544.76	C$-39,136,958.00	C($0.58)	-6.02
Microbix Biosystems	C$11.64 million	5.83	C$-5,581,797.00	C($0.05)	-12.16

Microbix Biosystems has higher revenue and earnings than IMV. Microbix Biosystems is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for IMV and Microbix Biosystems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMV	0	4	0	0	2.00
Microbix Biosystems	0	0	0	0	N/A

IMV currently has a consensus target price of C$5.08, indicating a potential upside of 46.07%. Given IMV's higher probable upside, research analysts plainly believe IMV is more favorable than Microbix Biosystems.

Profitability

This table compares IMV and Microbix Biosystems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMV	N/A	N/A	N/A
Microbix Biosystems	N/A	N/A	N/A

Microbix Biosystems vs. Fennec Pharmaceuticals Stock

Fennec Pharmaceuticals (TSE:FRX) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Fennec Pharmaceuticals and Microbix Biosystems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	N/A	N/A	N/A
Microbix Biosystems	N/A	N/A	N/A

Valuation & Earnings

This table compares Fennec Pharmaceuticals and Microbix Biosystems' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$170,000.00	1,235.91	C$-24,910,874.00	C($0.96)	-8.43
Microbix Biosystems	C$11.64 million	5.83	C$-5,581,797.00	C($0.05)	-12.16

Microbix Biosystems has higher revenue and earnings than Fennec Pharmaceuticals. Microbix Biosystems is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Fennec Pharmaceuticals and Microbix Biosystems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0	0	2	0	3.00
Microbix Biosystems	0	0	0	0	N/A

Microbix Biosystems vs. Resverlogix Stock

Microbix Biosystems (TSE:MBX) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations for Microbix Biosystems and Resverlogix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbix Biosystems	0	0	0	0	N/A
Resverlogix	0	0	0	0	N/A

Earnings & Valuation

This table compares Microbix Biosystems and Resverlogix's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbix Biosystems	C$11.64 million	5.83	C$-5,581,797.00	C($0.05)	-12.16
Resverlogix	N/A	N/A	N/A	C$0.01	80.91

Resverlogix has lower revenue, but higher earnings than Microbix Biosystems. Microbix Biosystems is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Microbix Biosystems and Resverlogix's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbix Biosystems	N/A	N/A	N/A
Resverlogix	N/A	N/A	N/A

Summary

Resverlogix beats Microbix Biosystems on 2 of the 3 factors compared between the two stocks.